

Publication of transfers of value to Recipients aims at reporting the values (monetary or in-kind) to Healthcare Professionals and Organisations our company is collaborating / has relationships with, following the objectives and provisions included in the applicable Codes. Individual disclosures have been consented to by individual Recipients – such consent has been given to allow complying with the applicable Codes that our company signed off to. These publications do not grant a general permission for those accessing our websites or the national platforms to undertake additional processing of the Recipient's data. For a good understanding of the reporting included in our disclosures as published on these websites, we refer to the Methodological Notes that clarify the meaning and content of the transfers of value reported.

Sanofi Cyprus Disclosure 2021											Date of publication:	30/6/2022	
	Full Name  <i>(Art. 1.01)</i>	HCPs:City of Principal Practice HCOs:city where registered  <i>(Art. 3)</i>	Country of Principal Practice  <i>(Schedule 1)</i>	Principal Practice Address  <i>(Art. 3)</i>	Unique country identifier OPTIONAL  <i>(Art. 3)</i>	Donations and Grants to HCOs <i>(Art. 3.01.1.a)</i>	Contribution to costs of Events <i>(Art. 3.01.1.b &amp; 3.01.2.a)</i>			Fee for service and consultancy <i>(Art. 3.01.1.c &amp; 3.01.2.c)</i>		TOTAL OPTIONAL	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
HCPs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up. Itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
						N/A	N/A					Optional	
	<i>OTHER, NOT INCLUDED ABOVE -where information cannot be disclosed on an individual basis for legal reasons</i>												
		Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02					N/A	N/A	0,00	0,00	0,00	0,00	0,00
		Number of Recipients in aggregate disclosure - Art. 3.02					N/A	N/A	0	0	0	0	N/A
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02					N/A	N/A	0.00%	0.00%	0.00%	0.00%	N/A	
HCOs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up. Itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
	Παγκύπριος Ιατρικός Σύλλογος	1087 Λευκωσία	Cyprus	Θόσου 17, Rita Court 15			4.500,00 EUR					4.500,00 EUR	
	<i>OTHER, NOT INCLUDED ABOVE -where information cannot be disclosed on an individual basis for legal reasons</i>												
		Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02					0,00	0,00	0,00	0,00	0,00	0,00	0,00
		Number of Recipients in aggregate disclosure - Art. 3.02					0	0	0	0	0	0	N/A
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02					0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	N/A	
R&D	<b>AGGREGATE DISCLOSURE</b>												
	Transfers of Value Research & Development as defined - Article 3.04 and Schedule 1												
	Optional												

Refer to attached Methodological Notes